BeOne Medicines (ONC) PT Raised to $412 at Truist Securities

Truist Securities raised its price target on BeOne Medicines (NASDAQ: ONC) to $412.00 (from $400.00) while maintaining a Buy rating.

The analyst commented: "Brukinsa Reset with Momentum Intact; Robust 2026 Setup - BTK CDAC Data/AA Filing & Solid Tumor Updates; ONC shares are under pressure today, likely driven by the $6.2-$6.4B FY26 rev guide which roughly brackets consensus (~$6.4B). That said, we view the outlook as suggesting a healthy Brukinsa growth, even without any major label expansion, and note that the guide already reflects emerging BTK competition, per mgmt in our 1x1. On pipeline, we look to pivotal data for BTK CDAC in CLL (1H26) and a potential AA filing (2H26), plus multiple solid tumor (CDK4i, PRMT5) and I&I (IRAK4 CDAC) readouts as directional catalysts into 2026. Incorporating the Q, FY26 guide, and insights from our post-EPS discussions, we adjust our PT to $412 (from $400) and reiterate our Buy rating."

You May Also Be Interested In

• Barclays Starts Centrus Energy Corp. (LEU) at Equalweight
• Barclays Starts Enliven Therapeutics (ELVN) at Overweight
• Mizuho Reiterates Outperform Rating on Uber Inc. (UBER)